APP Pharmaceuticals has received marketing approval for its generic anti-infective treatment, Aztreonam.
The Food and Drug Administration passed the product for injection in 1g 20ml and 2g 30ml strengths.
The company plans to launch Aztreonam, which is said to be therapeutically equivalent to the Bristol-Myers Squibb’s Azactam, immediately.
John Ducker, president and chief executive officer of APP Pharmaceuticals, said: “This approval reinforces APP’s commitment to provide our customers, and the patients they treat, with a consistently expanding portfolio of products.”
Aztreonam is used to treat urinary tract, gynecologic and skin infections.
APP Pharmaceuticals is a subsidiary of Fresenius Kabi Pharmaceuticals.
Copyright Press Association 2010